Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
20–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Fulfillment of entry criteria for the preceding yearly study
Male or female patients aged between 20 and 85 years
Known history of mild to moderate essential hypertension requiring drug treatment, WHO grade I to II
Controlled blood pressure (RR diastolic ≤ 90 mm Hg or 91 - 95 mm Hg and concurrent reduction in blood pressure of at least 10 mm compared to baseline level) during treatment with lacidipine at a dose of 2 - 6 mg once a day
Final visit of the previous yearly study (Visit 4) completed as scheduled
Informed consent to participate in the follow-up study
You may not be if
* Pregnancy, lactation, possibility of conception without the use of a scientifically recognised method of contraception
* Secondary form of hypertension
* Consumptive illness
* Clinically manifest concomitant cardiovascular illness, e.g.: aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy or any other condition hindering left ventricular outflow, aortic isthmus stenosis, severe (NYHA Class III or higher) or decompensated heart failure, clinically relevant hypo- or hyperkinetic cardiac arrhythmia
* Myocardial infarction or cerebrovascular accident within the 6 months prior to the start of the follow-up study
* Hypersensitivity to dihydropyridines
* Concomitant long-term treatment (\> 3 weeks) with antihypertensive substances not envisaged in the protocol (exception: short-acting nitrates), sedatives, tricyclic antidepressants
* Suspected alcohol, narcotic or drug abuse
Clareo Health | Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension
